Finerenone
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Finerenone and local guidelines before prescribing.
Mineralocorticoid antagonist
Mechanism
Non-steroidal mineralocorticoid receptor antagonist.
Uses
Chronic kidney disease with type 2 diabetes, heart failure with preserved EF.
Dosing
- Finerenone Type 2 diabetes with CKD | 10–20 mg daily (by eGFR), add-on to ACE inhibitor/ARB. Monitor potassium.
Endocrinology: Diabetes - Finerenone 10–20 mg daily | Type 2 diabetes with CKD and albuminuria, eGFR 25 or more, on ACEi/ARB and SGLT2i (TA877). Hyperkalaemia.
Renal: Chronic Kidney Disease
Side effects
Hyperkalaemia, hypotension, reduced eGFR, hyponatraemia.
Interactions
Strong CYP3A4 inhibitors contraindicated; potassium supplements.
Contraindications and cautions
Potassium above 5.0, Addison disease
Monitoring
Potassium, eGFR
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce start dose if eGFR 25–60
Overdose and reversal
Supportive
Special advice
Check potassium before starting and at 4 weeks.
More from the textbook: uses, cautions and other points
- Finerenone (a non-steroidal MRA) - add-on for type 2 diabetes with CKD and albuminuria (NICE TA877). Monitor potassium.
Endocrinology: Diabetes - Finerenone - a non-steroidal mineralocorticoid receptor antagonist; for CKD with type 2 diabetes and albuminuria (NICE TA) on top of an ACE inhibitor or ARB; reduces kidney and heart events; monitor potassium .
Renal: Anatomy, Physiology and Pharmacology - Finerenone | Non-steroidal MRA for diabetic CKD with albuminuria; monitor K.
Renal: Anatomy, Physiology and Pharmacology - Uses - HFrEF (improve survival), resistant hypertension, primary hyperaldosteronism, ascites; finerenone for diabetic kidney disease.
Cardiology: Anatomy Physiology and Pharmacology - Drugs - ACE inhibitors , ARBs , spironolactone , eplerenone, finerenone, amiloride , trimethoprim (blocks ENaC like amiloride), heparin (suppresses aldosterone), NSAIDs, ciclosporin and tacrolimus, potassium supplements and salt substitutes.
Renal: Anatomy, Physiology and Pharmacology - NICE TAs: dapagliflozin and empagliflozin for CKD; finerenone; potassium binders
Renal: Anatomy, Physiology and Pharmacology - 💡 Clinical Pearl: Modern diabetic kidney disease treatment has "four pillars": ACE inhibitor or ARB, SGLT2 inhibitor, finerenone, and a GLP-1 receptor agonist (semaglutide reduced kidney outcomes in the FLOW trial) - on top of BP, glucose and lipid control.
Renal: Chronic Kidney Disease - Causes - low eGFR, ACE inhibitors and ARBs, spironolactone, finerenone, trimethoprim, NSAIDs, diet, acidosis, constipation.
Renal: Chronic Kidney Disease
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Diabetes (2 mentions)
- Renal: Anatomy, Physiology and Pharmacology (4 mentions)
- Renal: Chronic Kidney Disease (8 mentions)
- Renal: Glomerular Disease (1 mention)